1. Home
  2. TYGO vs IFRX Comparison

TYGO vs IFRX Comparison

Compare TYGO & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tigo Energy Inc.

TYGO

Tigo Energy Inc.

HOLD

Current Price

$2.06

Market Cap

309.0M

Sector

Technology

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$2.05

Market Cap

266.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYGO
IFRX
Founded
2007
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
309.0M
266.6M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
TYGO
IFRX
Price
$2.06
$2.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$6.00
$6.25
AVG Volume (30 Days)
1.7M
1.4M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
97.12
N/A
EPS
N/A
N/A
Revenue
$103,536,000.00
N/A
Revenue This Year
$30.78
N/A
Revenue Next Year
$21.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
91.68
N/A
52 Week Low
$1.19
$0.74
52 Week High
$5.33
$2.95

Technical Indicators

Market Signals
Indicator
TYGO
IFRX
Relative Strength Index (RSI) 29.42 50.75
Support Level $1.97 $0.95
Resistance Level $2.39 $2.94
Average True Range (ATR) 0.21 0.23
MACD 0.01 0.01
Stochastic Oscillator 22.96 27.95

Price Performance

Historical Comparison
TYGO
IFRX

About TYGO Tigo Energy Inc.

Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: